Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers
- PMID: 1455904
- DOI: 10.3109/00498259209053145
Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers
Abstract
1. A quantitative h.p.l.c. plasma assay for oxybutynin (OB) and its active metabolite, N-desethyl oxybutynin (DEOB) is described. The method is linear with coefficients of variation ranging between 4 and 11.8% for OB and 4.6-9.1% for DEOB over the typical concentration range measured. Minimum detectable levels were 0.5 and 5 ng/ml for OB and DEOB respectively from a 2 ml sample. 2. Pharmacokinetic parameters were obtained after a single oral dose of OB and after administration two or three times daily to frail elderly and elderly volunteer groups respectively. Single dose results were also compared with data from young healthy volunteers. 3. There was a wide range in peak blood levels and high levels of parent drug were matched by high DEOB metabolite levels. Plasma levels on repeated administration were as would be predicted from the single dose kinetics. 4. Area under the plasma time course curve for DEOB metabolite was less than or equal to 5 than that of the parent drug. 5. A trend of increasing peak plasma levels and bioavailability was observed with increasing age and frailty, with the differences more apparent between the active elderly and frail elderly groups than between the active elderly and young volunteers. 6. Results indicate that for frail elderly patients a lower initial starting dose of 2.5 mg OB given two or three times a day may provide adequate therapeutic blood levels of the drug.
Similar articles
-
Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.J Clin Pharmacol. 1999 Mar;39(3):289-96. J Clin Pharmacol. 1999. PMID: 10073329 Clinical Trial.
-
In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin.Life Sci. 2005 Apr 8;76(21):2445-56. doi: 10.1016/j.lfs.2004.11.013. Life Sci. 2005. PMID: 15763076
-
Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.J Urol. 2001 Dec;166(6):2232-6. J Urol. 2001. PMID: 11696741
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).Br J Clin Pharmacol. 2004 Nov;58(5):452-69. doi: 10.1111/j.1365-2125.2004.02228.x. Br J Clin Pharmacol. 2004. PMID: 15521892 Free PMC article. Review. No abstract available.
Cited by
-
Oxybutynin topical gel in the treatment of overactive bladder.Open Access J Urol. 2010 Jun 16;2:91-8. Open Access J Urol. 2010. PMID: 24198618 Free PMC article. Review.
-
Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding.Int Neurourol J. 2012 Sep;16(3):107-15. doi: 10.5213/inj.2012.16.3.107. Epub 2012 Sep 30. Int Neurourol J. 2012. PMID: 23094215 Free PMC article.
-
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?Naunyn Schmiedebergs Arch Pharmacol. 2006 Nov;374(2):79-85. doi: 10.1007/s00210-006-0105-y. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 17021853 Review.
-
Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.Br J Pharmacol. 2000 Sep;131(2):245-54. doi: 10.1038/sj.bjp.0703595. Br J Pharmacol. 2000. PMID: 10991917 Free PMC article.
-
Urinary incontinence: oxybutynin topical gel for overactive bladder.Nat Rev Urol. 2009 Jul;6(7):351-2. doi: 10.1038/nrurol.2009.111. Nat Rev Urol. 2009. PMID: 19578347 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous